Venezuelan expert on leprosy dead at 100

Venezuelan scientist and doctor Jacinto Convit, renowned for developing a vaccine against leprosy, died on Monday in Caracas at the age of 100, his family said.

Convit won many international honors, including Spain's Prince of Asturias Award and France's Legion of Honor, and was tipped for the 1988 Nobel Prize for Medicine, although he did not win.

understanding of infectious and such as Leishmaniasis and Chagas.

In the past 15 years, he devoted much of his time looking for a cure for cancer.

"This disease prevents me from sleeping," he confided in 2013.

In a statement announcing his death, his family said that Convit had spent much of his career working to cure diseases threatening the native peoples of Venezuela's tropical forests and .

add to favorites email to friend print save as pdf

Related Stories

Canada's PM lauds Nobel laureate Steinman

Oct 03, 2011

Canada's prime minister paid tribute Monday to Canadian cell biologist Ralph Steinman, who died days before being awarded the Nobel Prize for Medicine for his pioneering work on the immune system.

Drive behind Nobel Medicine Prize say winners

Oct 07, 2013

A German-born neuroscientist who describes himself as "incredibly driven" was actually driving around in Spain when his phone rang Monday with the news that he'd won the Nobel Prize. ...

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.